SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : InterMune (nasdaq)ITMN

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: rkrw who wrote (105)6/29/2001 9:28:27 AM
From: tuck   of 508
 
>>BURLINGAME, Calif., June 29 /PRNewswire/ -- InterMune, Inc. (Nasdaq: ITMN - news) today announced the pricing of its public offering of 3,750,000 shares of common stock at a price to the public of $32.00 per share. All of the shares are being offered by the Company. InterMune also announced the pricing of its public offering of $130,000,000 aggregate principal amount of 5-3/4 percent convertible subordinated notes due 2006. The notes will be convertible into InterMune common stock at a conversion rate of approximately 26 shares per $1,000 principal amount, or $38.40 per share, subject to adjustment in certain circumstances.

The offering is being made through an underwriter group led by Lehman Brothers Inc., with Banc of America Securities LLC, Robertson Stephens, Inc. and UBS Warburg LLC co-managing the offering. The underwriters have the option to purchase up to an additional 545,896 shares of common stock and an additional $19,500,000 principal amount of convertible subordinated notes to cover over-allotments, if any.<<

snip

Cheers, Tuck
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext